Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 4Sarcoma 1Head & Neck 1Endocrine 1

Conditions

Parathyroid Neoplasms 1Multiple Endocrine Neoplasia 1Hypoglycemia 1Hyperparathyroidism 1Hypercalcemia 1

Interventions

Everolimus 25Magnetic Resonance Spectroscopy 13pembrolizumab 12pasireotide 12Sunitinib 11Octreotide 11lanreotide 10cabozantinib 10lenvatinib 8Sorafenib 8Cisplatin 8Temozolomide 7Etoposide 7Bevacizumab 7pazopanib 6Paclitaxel 6Nivolumab 6Doxorubicin 6Carboplatin 6Capecitabine 6vandetanib 5gallium Ga 68 dotatate 5Specimen Handling 5trametinib 4lutetium Lu 177 dotatate 4dabrafenib 4Mitotane 4Iodine-131 4telotristat ethyl 3surufatinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × fluorodopa F 18 × Endocrine × Clear all
NCT00001277 2022-06-07

Studies of Elevated Parathyroid Activity

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
1,553 enrolled 8 charts
EndocrineHead & Neck

Hypercalcemia, Hyperparathyroidism, Hypoglycemia, Multiple Endocrine Neoplasia, Parathyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡